Pharma News - Chemdiv

Researchers find oral antiviral drug that could provide an effective treatment against respiratory syncytial virus

An oral antiviral drug that targets a key part of the respiratory syncytial virus (RSV) polymerase and inhibits the synthesis of viral genetic material has been identified, a finding that could pro...

Otsuka, Lundbeck Tout Positive Phase III Results for Alzheimer's Drug

Otsuka Pharmaceutical and Lundbeck announced positive Phase III clinical trial results Monday regarding brexpiprazole (Rexulti) as a treatment for agitation in patients with Alzheimer’s dementia...

World Health Organization says monkeypox is not a global health emergency right now

The World Health Organization on Saturday said the rapid spread of monkeypox across dozens of nations does not represent a global health emergency at this time. ...

Galapagos Acquires CellPoint and AboundBio for Over $250 Million

Galapagos has inked purchase deals with two biotech companies, CellPoint and AboundBio, aimed at developing chimeric antigen receptor (CAR)-T therapies.

NICE Rejects Fampyra for Multiple Sclerosis

The UK’s National Institute for Health and Care Excellence (NICE) has declined to recommend Acorda Therapeutics’ multiple sclerosis drug Fampyra (fampridine) for National Health Service (NHS) ...

Erectile dysfunction drugs could help treat oesophageal cancer, study finds

Southampton scientists found that the PDE5 inhibitors in Viagra and other erectile dysfunction pills could treat oesophageal cancer.

Novartis faces threat of early generic of MS drug Gilenya in US

Novartis could lose years of patent protection in the US for its blockbuster multiple sclerosis therapy Gilenya, after a federal appeals verdict went against the company. ...

Enanta lawsuit claims Pfizer’s Paxlovid infringes its patent

S biotech Enanta Pharma has filed a lawsuit against Pfizer, claiming that its oral antiviral for COVID-19 Paxlovid infringes one of its patents and seeking damages from the pharma giant. ...

AbbVie files Qulipta for chronic migraine prevention

AbbVie has filed for approval of its oral CGRP inhibitor Qulipta for prevention of chronic migraine, seeking to leap ahead of its main rival in the class.

U.S. FDA Approves Merck’s Vaxneuvance (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Infants and Children

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for Vaxneuvance™(Pneumoc...

Paratek Pharma Shares Rise After Nuzyra Gets FDA Fast Track

Shares of Paratek Pharmaceuticals Inc. were trading higher in Tuesday's after-hours market, following news the U.S. Food and Drug Administration granted Fast Track designation for the oral and IV ...

Is Merck planning a $30bn-plus move for Seagen?

Speculation that Merck & Co may be preparing a $30 billion takeover bid for Seagen – bolstering its oncology ambitions – has the biopharma community aflutter. ...